Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (II).

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Revista de neurología (Ed. impresa)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 28675259
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (I).

  2017cited by this paper
• Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO

  2016cited by this paper
• Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis.

  2016cited by this paper
• Foxo3 Transcription Factor Drives Pathogenic T Helper 1 Differentiation by Inducing the Expression of Eomes.

  2016cited by this paper
• Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity

  2016cited by this paper
• Anoctamin 2 identified as an autoimmune target in multiple sclerosis

  2016cited by this paper
• Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease

  2016cited by this paper
• Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis

  2016cited by this paper
• Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.

  2016cited by this paper
• Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.

  2016cited by this paper
• Relationships between quantitative spinal cord MRI and retinal layers in multiple sclerosis

  2015cited by this paper
• Optimizing therapy early in multiple sclerosis: An evidence-based view.

  2015cited by this paper
• Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo

  2015cited by this paper
• Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy

  2015cited by this paper
• Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome

  2015cited by this paper
• Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four‐year study

  2015cited by this paper
• A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity

  2015cited by this paper
• B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes

  2014cited by this paper
• Street-Experienced Peripheral B Cells Traffic to the Brain

  2014cited by this paper
• Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

  2014cited by this paper
• Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis

  2014cited by this paper
• Pervasive axonal transport deficits in multiple sclerosis models.

  2014cited by this paper
• Neurons as targets for T cells in the nervous system.

  2013cited by this paper
• Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?

  2013cited by this paper
• Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies?

  2013cited by this paper
• Increased PK11195 PET binding in the cortex of patients with MS correlates with disability

  2012cited by this paper
• Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study

  2011cited by this paper
• Neurodegeneration in autoimmune CNS inflammation.

  2010cited by this paper
• Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS?

  2010cited by this paper
• Multiple sclerosis - candidate mechanisms underlying CNS atrophy.

  2010cited by this paper
• Evidence for a two-stage disability progression in multiple sclerosis

  2010cited by this paper
• Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial

  2009cited by this paper
• Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients

  2007cited by this paper
• The window of therapeutic opportunity in multiple sclerosis

  2005cited by this paper

• Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (I).

  2017cites this paper